financetom
Business
financetom
/
Business
/
Estee Lauder Cos Unusual Options Activity For March 11
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Estee Lauder Cos Unusual Options Activity For March 11
Mar 11, 2024 1:01 PM

Investors with a lot of money to spend have taken a bullish stance on Estee Lauder Cos ( EL ) .

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with EL, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 10 uncommon options trades for Estee Lauder Cos ( EL ).

This isn't normal.

The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.

Out of all of the special options we uncovered, 3 are puts, for a total amount of $299,200, and 7 are calls, for a total amount of $1,295,908.

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $135.0 to $220.0 for Estee Lauder Cos ( EL ) over the last 3 months.

Volume & Open Interest Development

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Estee Lauder Cos's ( EL ) options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Estee Lauder Cos's ( EL ) whale trades within a strike price range from $135.0 to $220.0 in the last 30 days.

Estee Lauder Cos Option Activity Analysis: Last 30 Days

Noteworthy Options Activity:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
EL CALL SWEEP BULLISH 06/21/24 $155.00 $327.5K 2.9K 1.4K
EL CALL TRADE BULLISH 06/21/24 $155.00 $324.2K 2.9K 1.2K
EL CALL SWEEP BULLISH 06/21/24 $155.00 $319.5K 2.9K 1.7K
EL PUT TRADE BEARISH 04/19/24 $150.00 $220.0K 713 602
EL CALL SWEEP BULLISH 06/21/24 $155.00 $121.0K 2.9K 857

About Estee Lauder Cos

Estee Lauder ( EL ) is a leader in the global prestige beauty market, participating across skin care (52% of 2023 sales), makeup (28%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estee Lauder ( EL ), Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 28% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 33% from Asia-Pacific. Estee Lauder ( EL ) sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.

Having examined the options trading patterns of Estee Lauder Cos ( EL ), our attention now turns directly to the company. This shift allows us to delve into its present market position and performance

Present Market Standing of Estee Lauder Cos

Trading volume stands at 1,497,965, with EL's price up by 0.35%, positioned at $150.02.

RSI indicators show the stock to be is currently neutral between overbought and oversold.

Earnings announcement expected in 51 days.

Professional Analyst Ratings for Estee Lauder Cos

In the last month, 3 experts released ratings on this stock with an average target price of $167.66666666666666.

In a cautious move, an analyst from DA Davidson downgraded its rating to Buy, setting a price target of $179.

An analyst from DA Davidson has revised its rating downward to Buy, adjusting the price target to $179.

An analyst from Goldman Sachs has revised its rating downward to Neutral, adjusting the price target to $145.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Estee Lauder Cos ( EL ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Badger Meter's Q1 Earnings, Net Sales Rise
Badger Meter's Q1 Earnings, Net Sales Rise
Apr 18, 2024
08:48 AM EDT, 04/18/2024 (MT Newswires) -- Badger Meter ( BMI ) reported Q1 earnings Thursday of $0.99 per diluted share, up from $0.66 a year earlier. Four analysts polled by Capital IQ expected $0.84. Net sales for the quarter ended March 31 were $196.3 million, up from $159.1 million a year earlier. Analysts surveyed by Capital IQ expected $182.3...
Next Yen Intervention Likely Worth 'Six Big Figures' in USD/JPY, Says Spectra Markets
Next Yen Intervention Likely Worth 'Six Big Figures' in USD/JPY, Says Spectra Markets
Apr 18, 2024
08:48 AM EDT, 04/18/2024 (MT Newswires) -- The Japanese yen (USD/JPY) could rise another six yen against the dollar in the event of any further currency intervention from the Ministry of Finance but selling EUR/JPY is a better way to trade this, according to Spectra Markets' Brent Donnelly. Japan's yen underperformed all other G10 currencies after USD/JPY rose 0.1% to...
Wishpond Technologies Q4 Adjusted Ebitda Plunges as Expenses Rise
Wishpond Technologies Q4 Adjusted Ebitda Plunges as Expenses Rise
Apr 18, 2024
08:49 AM EDT, 04/18/2024 (MT Newswires) -- Wishpond Technologies ( WPNDF ) on Thursday reported a steep drop in fourth-quarter adjusted Ebitda as sales and marketing expenses increased and the company faced higher costs related to the development and imminent beta launch of SalesCloser AI. Adjusted Ebitda for the three months ended Dec. 31 fell to $14,807 from $687,335 in...
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi
Apr 18, 2024
08:48 AM EDT, 04/18/2024 (MT Newswires) -- TG Therapeutics ( TGTX ) said Thursday that it has been awarded a contract potentially worth about $186.8 million for Briumvi to be the preferred anti-CD20 agent listed on the Department of Veterans Affairs' National Formulary to treat patients with relapsing forms of multiple sclerosis. The one-year contract, which starts June 17, includes...
Copyright 2023-2026 - www.financetom.com All Rights Reserved